Alla studier
RekryteringTerapeutisk bekräftande (Fas III)Interventionell

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients with Hereditary Angioedema Type I or II A Pharmacokinetic Subtrial in Adolescent Patients with Hereditary Angioedema Type I or II Participating in the KVD900-302 Trial

This research is an ongoing study to see how safe a new medicine, KVD900, is when taken over a longer period. KVD900 is a tablet designed to treat sudden swelling attacks in people who have a condition called Hereditary Angioedema (HAE) Type 1 or 2. The study involves both adults and teenagers. For teenagers specifically, the researchers are also looking at how their bodies process the medicine. The main goal is to keep an eye on any side effects and understand how patients are generally doing while taking KVD900 for their HAE attacks.

Överblick

Status
Rekrytering
Fas
Terapeutisk bekräftande (Fas III)
Sponsor
Kalvista Pharmaceuticals Limited
Inskrivningsmål
75
Starta
26 Feb 2024

Vad handlar denna studie om?

This study is about a medicine called KVD900, which is being tested for people who have a condition called Hereditary Angioedema (HAE) Type 1 or 2. HAE is a rare genetic condition that causes sudden and unpredictable swelling in different parts of the body, such as the face, hands, feet, tummy, or airways, which can be very painful and sometimes dangerous.

The medicine, KVD900, is an oral tablet, meaning you take it by mouth. It's designed to be used "on-demand" – so when you feel an HAE attack starting. This study is an "open-label extension trial," which means that everyone taking part knows they are receiving the actual study medicine, KVD900. It's an extension because it allows people who have been in previous studies with KVD900 to continue taking it for a longer time.

The main purpose of this study is to closely monitor the safety of KVD900 over a longer period. The researchers want to see if there are any side effects, how often they occur, and if anyone needs to stop taking the medicine because of them. They will also be checking blood test results and general health signs like blood pressure regularly. For teenagers specifically, there's an additional part of the study (called a "subtrial") to understand how their bodies handle and use the medicine.

Viktiga punkter

  • This study is testing the long-term safety of KVD900 for HAE Type 1 or 2.
  • KVD900 is a tablet taken at the start of an HAE swelling attack.
  • It's an extension study for people previously in KVD900 trials.
  • Researchers will monitor side effects and overall health.
  • Teenagers will have extra checks to see how their bodies handle the medicine.
  • Participation involves regular visits and health assessments.

Vem kan vara berättigad?

To be part of this study, you generally need to be an adult, aged 18 years or older. There might be some specific requirements for teenagers due to the additional part of the study focused on how young bodies process the medicine.

Since this is an "extension" study, it means that you would typically have already taken part in an earlier study for KVD900. This helps the researchers continue to gather long-term information on people who are already familiar with the medicine.

Both males and females can take part. The most important health requirement is that you must have been diagnosed with Hereditary Angioedema Type 1 or Type 2. The study team will check your full medical history and current health to make sure it's safe for you to join.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Are you 18 years old or older? (Or a teenager specifically asked to join the adolescent subtrial?)
  2. Have you been diagnosed with Hereditary Angioedema Type 1 or Type 2?
  3. Have you previously taken part in a KVD900 study?
  4. Are you able to attend regular study visits and follow instructions?
  5. Are you willing to take the study medicine as directed?
  6. Are you comfortable with blood tests and physical examinations?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you join this study, you would continue to take the study medicine, KVD900, by mouth when you experience an HAE attack. You would have regular check-ups with the study team. These visits will involve various assessments, including physical examinations, blood tests, and checking your vital signs like blood pressure and heart rate. These checks help the researchers understand how you are responding to the medicine and if there are any safety concerns.

You would also be asked to keep track of your HAE attacks and how well the medicine works for you. The study will look at how quickly your symptoms improve after taking KVD900. The total duration of your participation would depend on the study plan, but because it's an extension study, it's designed to gather long-term information.

Potentiella risker och fördelar

Taking part in this study may offer potential benefits, such as continued access to a new on-demand treatment for your HAE attacks that might effectively relieve your symptoms. However, like all medicines, KVD900 may have potential side effects. These could include common side effects, or possibly more serious but rare ones, and the study aims to carefully monitor these. You will be told about all known risks before you decide to join. It is very important to remember that participating in any study is completely voluntary, and you have the right to withdraw at any time, for any reason, without affecting your regular medical care.

Platser (13)

Vissa platsangivelser är ungefärliga. Vi arbetar på att förbättra detta — vänligen kontrollera med testteamet innan du reser.
  • —
    Obekräftad
    Slovakien
  • —
    Obekräftad
    Nederländerna
  • —
    Obekräftad
    Italien
  • —
    Obekräftad
    Bulgarien
  • —
    Obekräftad
    Ungern
  • —
    Obekräftad
    Österrike
  • —
    Obekräftad
    Tyskland
  • —
    Obekräftad
    Grekland
  • —
    Obekräftad
    Polen
  • —
    Obekräftad
    Rumänien
  • —
    Obekräftad
    Frankrike
  • —
    Obekräftad
    Spanien

Vanliga frågor

Vad är Hereditärt Angioödem (HAE)?

HAE is a rare condition that causes sudden swelling in different parts of your body, which can be painful and sometimes serious.

Vad är KVD900?

KVD900 is an investigational medicine in tablet form, being studied to treat HAE swelling attacks when they happen.

Är denna medicin tillgänglig för alla?

No, KVD900 is currently a study medicine and is not yet available as a standard treatment.

Why is this an 'extension' study?

It means people who were in earlier KVD900 studies can continue taking the medicine to gather more information on its long-term safety.

Kommer jag att veta om jag får den riktiga medicinen?

Yes, this is an 'open-label' study, so everyone involved knows they are receiving KVD900.

Hur du får reda på mer

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "An Open-label Extension Trial to Evaluate the Long-term Safe…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.